Inceptionr LLC Lowers Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD)

Inceptionr LLC cut its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 72.9% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 13,778 shares of the biopharmaceutical company’s stock after selling 37,014 shares during the quarter. Inceptionr LLC’s holdings in Amicus Therapeutics were worth $130,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in shares of Amicus Therapeutics in the fourth quarter worth approximately $132,000. HealthInvest Partners AB grew its holdings in shares of Amicus Therapeutics by 18.6% in the fourth quarter. HealthInvest Partners AB now owns 326,840 shares of the biopharmaceutical company’s stock valued at $3,076,000 after acquiring an additional 51,368 shares in the last quarter. Y Intercept Hong Kong Ltd grew its holdings in shares of Amicus Therapeutics by 245.5% in the fourth quarter. Y Intercept Hong Kong Ltd now owns 120,958 shares of the biopharmaceutical company’s stock valued at $1,139,000 after acquiring an additional 85,951 shares in the last quarter. Transcend Capital Advisors LLC grew its holdings in shares of Amicus Therapeutics by 11.3% in the fourth quarter. Transcend Capital Advisors LLC now owns 363,913 shares of the biopharmaceutical company’s stock valued at $3,428,000 after acquiring an additional 37,059 shares in the last quarter. Finally, Legacy Capital Group California Inc. grew its holdings in shares of Amicus Therapeutics by 20.2% in the fourth quarter. Legacy Capital Group California Inc. now owns 23,229 shares of the biopharmaceutical company’s stock valued at $219,000 after acquiring an additional 3,900 shares in the last quarter.

Amicus Therapeutics Price Performance

Shares of NASDAQ FOLD opened at $8.63 on Tuesday. The stock has a fifty day simple moving average of $9.42 and a two-hundred day simple moving average of $10.22. Amicus Therapeutics, Inc. has a 1-year low of $8.55 and a 1-year high of $12.65. The firm has a market cap of $2.65 billion, a price-to-earnings ratio of -47.94, a price-to-earnings-growth ratio of 1.51 and a beta of 0.69. The company has a current ratio of 3.39, a quick ratio of 2.42 and a debt-to-equity ratio of 2.01.

Analyst Ratings Changes

Several equities analysts have recently issued reports on the company. StockNews.com lowered Amicus Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, February 20th. Needham & Company LLC reaffirmed a “hold” rating on shares of Amicus Therapeutics in a report on Thursday, February 20th. JPMorgan Chase & Co. upped their target price on Amicus Therapeutics from $16.00 to $17.00 and gave the company an “overweight” rating in a report on Tuesday, November 12th. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $21.00 target price on shares of Amicus Therapeutics in a report on Wednesday, January 15th. Finally, Morgan Stanley reissued an “equal weight” rating and set a $12.00 price objective (down from $17.00) on shares of Amicus Therapeutics in a report on Friday, December 13th. Three equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $16.75.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.